S. Lipkowitz

TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers

This study shows TRAIL treatment of TNBC cells activates the NFKB2 pathway, leading to cytokine production that enhances neutrophil chemotaxis and immune suppression.

Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients

The paper identifies spatial interactions between NOS2, COX2, and T-effector cells in ER- breast cancer, linking these patterns to poor patient outcomes and suggesting potential therapeutic strategies.

NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer

This study identifies NOS2 and COX2 as key spatial targets in ER- breast cancer that influence immune phenotypes and clinical outcomes through spatial analysis of tumor microenvironments.

SMALL MOLECULE CLPP AGONISTS INDUCE SENESCENCE AND ALTER TRAIL-MEDIATED APOPTOTIC RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS

This paper shows that ClpP activators induce senescence in triple-negative breast cancer cells and enhance their sensitivity to TRAIL-mediated apoptosis.

NOS2 and COX2 Blockade Limits TNBC Disease Progression and Alters CD8+ T Cell Spatial Orientation and Density

This paper shows that blocking NOS2 and COX2 reduces TNBC tumor growth and improves CD8+ T cell infiltration and spatial distribution in tumors.

Mitochondrial Matrix Protease ClpP Agonists inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

This study shows that ClpP agonists inhibit breast cancer stem cell function by disrupting mitochondrial homeostasis and multiple metabolic pathways.

Flotillin-2 regulates EGFR activation, degradation, and cancer growth

This study shows that Flotillin-2 negatively regulates EGFR activation, ubiquitination, trafficking, and degradation, thereby suppressing cancer growth.

Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP

This paper characterizes TR-107, a novel ClpP activator, showing potent antitumor effects against triple-negative breast cancer through mitochondrial metabolic disruption.